We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current B1MR34 market cap is 39.4B. The company's latest EPS is USD 0.8900 and P/E is 92.69.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 505.34M | 537.54M | 596.42M | 595.28M | 581.33M |
| Operating Income | -36.52M | -24.5M | 59.35M | 58.87M | 25.66M |
| Net Income | -6.65M | -249k | 50.85M | 56.04M | 40.38M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.7B | 1.86B | 1.85B | 2.1B | 2.42B |
| Operating Income | -126.04M | -96.27M | -20.41M | 41.56M | 185.8M |
| Net Income | -23.85M | 859.1M | -2.15M | 141.56M | 167.65M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 6.26B | 6.38B | 6.43B | 6.56B | 6.76B |
| Total Liabilities | 1.7B | 1.77B | 1.77B | 1.78B | 1.86B |
| Total Equity | 4.57B | 4.6B | 4.66B | 4.78B | 4.9B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 4.69B | 5.85B | 6B | 6.38B | 6.84B |
| Total Liabilities | 1.57B | 1.74B | 1.73B | 1.77B | 1.89B |
| Total Equity | 3.12B | 4.11B | 4.27B | 4.6B | 4.95B |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 169.12M | 175.9M | -73.93M | -3.87M | 131.78M |
| Investing | 34.68M | -20.03M | -30.01M | -482k | -46.28M |
| Financing | -29.52M | -18.65M | -40.74M | -28.78M | -29.57M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 48.26M | 85.37M | 304.54M | 175.9M | 159.26M |
| Investing | -31.03M | -53.62M | -366.31M | -20.03M | -111.24M |
| Financing | -74.67M | 181.12M | -48k | -18.65M | -18.73M |
| Market Cap | 39.4B |
| Price to Earnings Ratio | 92.69 |
| Price to Sales Ratio | 6.42 |
| Price to Cash Ratio | 20.58 |
| Price to Book Ratio | 3.14 |
| Dividend Yield | - |
| Shares Outstanding | 188.37M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 504 |
| 52 Week Change | -12.05% |
| 52 Week High | 245.14 |
| 52 Week Low | 195.19 |
| Spread (Intraday) | -0.04 (-0.02%) |
| Company Name | Biomarin Pharmaceutical Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.biomarin.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
